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Abstract
Background: Hepatitis E virus (HEV) has emerged as an important cause of epidemic and sporadic acute viral
hepatitis worldwide. This study investigated the seroprevalence of anti-HEV in a Korean population and compared
the performance of two commercially available anti-HEV assays.
Methods: A total 147 health-check examinees were randomly sampled as matched to the age- and sex- adjusted
standard population based on the Korean National Census of 2007. Serum immunoglobulin G anti-HEV was
determined by using the Genelabs assay (Genelabs, Singapore) and the Wantai assay (Wantai, Beijing, China).
Results: The overall anti-HEV seroprevalence was 23.1% (95% CI, 16.1-30.1%) using the Wantai assay and 14.3%
(95% CI, 8.3-20.3%) using the Genelabs assay. Only 12 samples (8.1%) were positive for anti-HEV as measured by
both assays; agreement between the two assays was poor (kappa value of 0.315). The anti-HEV seroprevalence
increased with age from 2% and 3% in the people younger than 20-years-of-age to 34.6% and 42.3% in those over
59-years-of-age by the Genelabs and Wantai assay, respectively.
Conclusions: The HEV seroprevalence in Korean population is about 20% overall, with seroprevalence increasing in
this population with increasing age. There was poor concordance in the results of the Genelabs and Wantai assays,
which warrants further study concerning a reliable diagnostic test for the diagnosis of hepatitis E.
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Background
Hepatitis E virus (HEV) is an emerging disease of global
importance as a major cause of enterically transmitted
hepatitis [1]. After its discovery in 1983 [2], HEV was
characterized as a non-enveloped, single stranded, posi-
tive sense RNA virus classified as a member of the
Hepeviridae family, Hepevirus genus.
The epidemiology of HEV infection displays two pat-
terns. The first is an outbreak pattern in areas of high
endemicity (primarily via water-borne or fecal-to-oral
transmission). The second is a sporadic pattern that
occurs worldwide via zoonotic transmission and food
borne transmission. Hepatitis E is a serious public
health problem responsible for over 50% of acute viral
hepatitis cases [3] in endemic countries, which includes
large parts of Asia, Africa, the Mediterranean region,
Mexico, and South America [4]. In contrast, HEV infec-
tion has previously been considered rare in developed
countries [5], but is far more common than previously
recognized [6,7]. Zoonotic transmission, especially from
pigs, has been suggested [8]. However, the true burden
of infection and its implication on public health impact
remain undefined.
In developed countries, anti-HEV immunoglobulin G
(IgG) prevalence rates range between 3% to above 20%
[7,9,10]. These appear to be higher than those expected
from the low rate of clinically evident hepatitis E disease
in developed countries, suggesting that subclinical or
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unrecognized infection is common [11]. Although sev-
eral cases of imported and locally acquired hepatitis E
have been reported in Korea, the anti-HEV seropreva-
lence data have not been available due to lack of disease
recognition and to the limited availability of diagnostic
tools [12].
Several anti-HEV assays have been developed and are
available for use. However, the performance of each
anti-HEV assay has not been well studied. One study
[13] reported highly variable results among the different
assays, which suggested that the diagnosis of HEV infec-
tion using anti-HEV tests should be made with caution.
Findings from a comparison of two commercially avail-
able IgG anti-HEV enzyme-linked immunosorbent assay
(EIA) kits – the Genelabs EIA (Genelabs, Singapore) and
the Wantai EIA (Wantai Biological Pharmacy Enterprise,
Beijing, China) – demonstrated that the Wantai EIA was
more sensitive than the Genelabs EIA, and produced
positive results for a longer time post-infection [14].
Despite these findings, the Genelabs anti-HEV EIA
remains the more popular assay.
The aims of this study were to investigate the sero-
prevalence of anti-HEV and its related factors in a Ko-
rean population, and to again compare the results of the
two aforementioned commercially available serological
assays for the detection of HEV-specific IgG.
Methods
Subjects and serum samples
A total of 484 health-check examinees visiting the
Health Promotion Center of Seoul National University
Bundang Hospital from June 2006 to September 2006
and agreed to participate in this study were enrolled.
Among them, 147 sera were randomly selected by
matching the subjects to the age- and sex- adjusted
standard population of the Korean National Census of
2007. In detail, 484 subjects were first allocated into the
each category of age in decades and sex, and then 147
were randomly selected according to the proportions of
the standard population in each category. Serum sam-
ples were stored at −70°C until the analysis. Informed
consent was obtained from all participants and the study
protocol was approved by the Institutional Review Board
of Seoul National University Bundang Hospital.
Measurement of anti-HEV IgG using the two commercial
assays
The Genelabs HEV IgG enzyme-linked immunosorbent
assay (ELISA) and the Wantai HEV IgG ELISA were
used to detect IgG anti-HEV in sera. The Genelabs assay
detects antibodies directed at a mixture of recombinant
peptides specified by the open reading frame (ORF) 2
and ORF 3 obtained from two different strains of HEV:
one from Mexico (genotype 2) and the other from
Burma (genotype 1) [15]. The Wantai assay uses a re-
combinant peptide corresponding to amino acid resi-
dues 396–606 of the major structural protein specified
by ORF2 derived from a Chinese isolate of HEV (geno-
type 4) [16]. Anti-HEV IgG in all serum samples were
examined with both the Genelabs and Wantai assay,
according to manufacturer’s instructions, with three
negative and two positive control wells included on each
plate. The optical density (OD) of each sample was
determined at 450 nm. Samples with an OD greater
than the cut-off value were determined to be positive.
All serum samples were tested in duplicate and the cut-
off value was calculated to be the mean absorbance
value of the negative control plus 0.5 for the Genelabs
assay and plus 0.16 for the Wantai assay, according to
the manufacturer’s instructions.
Statistical analyses
Descriptive statistics were reported and agreement be-
tween two assays was quantified with the kappa statistic.
The chi-squared test and paired T-test were used to de-
termine whether any patient characteristics were asso-
ciated with different results in the two assays.
Differences were considered to be statistically significant
at P< 0.05. The statistical analyses were carried out
using the SPSS statistical program, version (SPSS,Chi-
cago, IL, USA).
Results
The study subjects included 72 males and 75 females,
with an overall mean age of 45 years. These characteris-
tics were compatible with the data from the Korean Na-
tional Census of 2007. The mean body mass index of the
subjects was 23.0, and the mean serum levels of alanine
aminotransferase and total bilirubin were 28.4 IU/mL
and 1.0 mg/dL, respectively. The hepatitis B virus sur-
face antigen (HBsAg) positive rate was 3.8%, and the
anti-hepatitis C virus antibody positive rate was zero.
The overall seroprevalence of anti-HEV IgG in the
population, which was age- and sex-adjusted to the
standard population of Korea according to 2007 Census
results, was 23.1% (34/147; 95% CI, 16.1-30.1%) using
the Wantai assay and 14.3% (21/147; 95% CI, 8.3-20.3%)
using the Genelabs assay. The comparison of the sero-
positive samples of anti-HEV measured using the two
assays are summarized in Table 1. Twelve subjects
(8.2%) were positive and 104 subjects were negative for
anti-HEV measured by both assays. The agreement be-
tween the Wantai and the Genelabs assay was poor, with
a κ value of 0.315.
Data on the anti-HEV seropositive rates according to
age groups and gender are summarized in Table 2. The
anti-HEV positive rates increased significantly according
to the increase of the age (P= 0.011 in the Wantai assay,
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P= 0.029 in the Genelabs assay). The anti-HEV seroposi-
tive rate in males tended to be higher than that in
females for both assays (P= 0.089 in the Wantai assay,
P= 0.201 in the Genelabs assay). The mean OD values
also showed a higher tendency in older age group and
men in both assays (Figure 1). There was no relationship
between the anti-HEV seropositivity and the presence of
hepatitis B or C markers, or ALT level.
Discussion
In this study, we evaluated the anti-HEV IgG positive
rate in a Korean adult population composed of 147
health check examinees, age- and sex-adjusted to the
standard population based on the Korean National Cen-
sus of 2007. The seropositivity of anti-HEV in our study
subjects was 23.1% in the Wantai assay and 14.3% in
the Genelabs assay. The agreement of the results be-
tween assays was poor, with a κ value of 0.315. The
anti-HEV positivity and mean OD values of anti-HEV
measured using both assays significantly increased with
increasing age.
Korea is not an endemic area of hepatitis E, and less
than 20 cases of acute hepatitis E cases have been
reported in South Korea since 2002 [17-20]. Most of
these cases were of Korean origin rather than having
been imported from highly endemic areas. Among them,
only a few cases demonstrated HEV RNA, which identi-
fied HEV genotype 3 and genotype 4, and genotype 3
HEV sequences isolated from human cases were nearly
identical to those from pigs in Korea. Moreover, we re-
cently reported a case of genotype 4 HEV hepatitis after
ingestion of raw bile juice of wild boar, suggesting zoo-
notic transmission of HEV in Korea [21,22]. Therefore,
at least two HEV genotypes already circulate in Korea,
and it is likely that more cases will be identified with the
increased recognition of HEV.
Previous studies on the seropositivity of anti-HEV in
Korea reported a positive rate between 8% and 17% in
the various populations, based on blood donors, or
healthy adults visiting some diagnostic laboratories.
However, those study subjects had not been adjusted to
the standard population and even no detailed demo-
graphic information had been provided; all these prelim-
inary studies had only used the Genelabs assay [23-25].
Therefore, direct comparison of our data to the previous
results was difficult. Recently, the comparative sero-
prevalence in 1,500 people over 40-years-of-age living in
Japan, Korea, and China were reported using anEIA
developed in Japan [26]. The anti-HEV positivity was
50.7% in Korean Chinese, 34% in South Koreans, and
14.3% in Koreans living in Japan. In our study, the sero-
prevalence of anti-HEV in adults over 40-years-of-age
was 16.9% in the Genelabs assay and 30.3% in the Wan-
tai assay, which was similar to the previous results.
Presently, older age groups tended to have higher HEV
seroprevalence rates by both assays, and the differences
were statistically significant. Age has been correlated
with higher HEV seroprevalence rates [27]. IgG anti-
HEV titers remain high from 1–4.5 years after the acute
Table 1 Comparison of seropositivity of anti-HEV IgG
measured using the two immunoassays
Anti-HEV assays Wantai positive Wantai negative Total, n
(%)n (%) n (%)
Genelabs positive 12 (8.2) 9 (6.1) 21 (14.3)
n (%)
Genelabs negative 22 (15.0) 104 (70.7) 126 (85.7)
n (%)
Total, n (%) 34 (23.1) 113 (77.9) 147 (100)
n, number.
A κ value of 0.315 for the agreement between the Wantai and the Genelabs
assay results.




Wantai% (95% CI) P-value Genelabs% (95% CI) P-value
Age group, years 0.011 0.029
20-29 24 12.5 (0–25.5) 8.3 (0–19.3)
30-39 34 11.8 (0.8-22.8) 11.8 (0.8-22.8)
40-49 41 19.5 (0–31.5) 9.8 (0.8-18.8)
50-59 22 31.8 (12.8-50.8) 9.1 (0–21.1)
> 59 26 46.1 (27.1-65.1) 34.6 (16.6-52.6)
Gender 0.089 0.201
male 72 29.1 (19.1-39.1) 18.1 (9.1-27.1)
female 75 17.3 (9.3-25.3) 11.7 (4.7-18.7)
Total 147 23.1 (16.1-30.1) 14.3 (8.3-20.3)
CI, confidence interval.
P values by chi-square test.
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phase [28], and one study detected anti-HEV IgG in
about 47% of individuals 14 years after acute HEV infec-
tion [29]. These persistent anti-HEV IgG can account
for the high rates of seroprevalence in older subjects
among the general population [30]. Therefore, differ-
ences in seroprevalence rates between different popula-
tions must be interpreted with caution [31], because
demographic variables, such as age, are related to the
prevalence, and because the assays vary in their
sensitivity [1] in the absence of standardized commer-
cially available confirmatory assays, such as reverse
transcription-PCR.
Several commercial serological assays for the detection
of anti-HEV IgG are available [32]. Among them, the
Genelabs EIA has been the most commonly used world-
wide. Its antigens use polypeptides from the C-terminal
ORF3 and ORF2 domains of HEV genotypes 1 and 2
[15]. The Genelabs assay, based on genotypes 1 and 2,
vary greatly in sensitivity (50%-90%) despite an excellent
specificity (93%-100%) [15,33-35]. Moreover, the experi-
ence and test performance with this assay has come
mainly from regions of high endemicity and western
countries. In our results, the agreement between the
Wantai and the Genelabs assays was poor (κ value =
0.315), and the Wantai assay displayed higher seroposi-
tivity than the Genelabs assay, which may suggest the
higher sensitivity of the Wantai assay. However, we did
not use the standard serum in our study, so that the sen-
sitivity and specificity in our study cannot be assessed.
Recently, Bendall et al. [14] compared the performance
of Genelabs and Wantai HEV IgG EIA kit using World
Health Organization standard sera; the Wantai assay
was more sensitive than the Genelabs assay, and contin-
ued to test infected individuals as positive for longer per-
iods post-infection. The authors also tested 500 blood
samples obtained from blood donors in the United
Kingdom using both assays; the Wantai assay resulted in
a substantially higher estimate of seroprevalence (16.2%)
than that of Genelabs (3.6%) [14]. Moreover, the Wantai
kit has been reported to be more sensitive because the
peptides used in the Wantai assay may associate into
dimers, which react more strongly with HEV reactive
sera than the linear monomeric antigens used in the
Genelabs assay [36]. The Wantai anti-HEV IgG ELISA
uses a peptide encoded by a structural region of ORF-2
of HEV genotype 4. Specificity is difficult to assess in
situations other than acute hepatitis E because there is
no gold standard for checking the specificity of the
current anti-HEV ELISA. Both assays have been com-
pared to Western blots and other assays in population-
based studies. The specificity of the Genelabs assay was
97% [37] and that of the Wantai assay was 99.6%
[16,38]. Accepting that both assays have similar specifici-
ties, it is reasonable to assume that the Wantai assay
gives a more reliable estimate of anti-HEV seropositivity
rates than the Genelabs assay.
The results of this study should be interpreted in the
context of its limitations. First, the data were obtained
from a single center using cross-sectional design, so
that time trends could not be addressed. However, dir-
ect measurement of incidence of hepatitis E is difficult
because infection is most often asymptomatic and
unrecognized. Second, we were unable to assess the
distribution of risk factors in our study population,
such as profession, hobbies, diet, social status, resi-
dence, or travel history. Further studies are required to
clarify the epidemiology and risk factors for HEV infec-
tion in Korea.
Conclusions
In conclusion, the prevalence of anti-HEV in Korean adult
population was about 20%, with higher prevalence at
Figure 1 The estimated mean values of optical density (OD) of anti-HEV IgG measured using Wantai and Genelabs immunoassays
according to age and gender in a Korean adult population. A, B. The mean OD values of anti-HEV IgG showed significant increase according
to the increase of the age in both assays (P value = 0.002 in the Wantai assay, P value = 0.003 in the Genelabs assay; P values calculated by
ANOVA). The overall OD values were higher in men than woman, with no significant difference between the two in both assays.
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increased age. However, different assays for the detection
of anti-HEV IgG result in significantly different results.
Therefore, future studies on the development of standard
diagnostic tests and their validation are warranted.
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